Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States.

Hoog M, Smith JL, Yu M, Peleshok J, Mody R, Grabner M

Clinical therapeutics24 May 2022Cited by 2 (Europe PMC)

PMID35618571DOI10.1016/j.clinthera.2022.04.005PepBankPUB-35618571

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyEfficacy outcome
In adults with ≥3 prior OAD classes, dulaglutide initiation was linked to an HbA1c reduction of -1.01%.
In plain wordsIn adults with at least three prior oral drug classes, dulaglutide initiation was linked to lower blood sugar than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change, at least three prior OAD classes
Study
n = 1,329
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg or 1.5 mg once weekly · injection · 6 monthsAs given in this study (human).
Measurements
HbA1c change
−1.01%
≥3 OAD cohort
95% CI lower
−1.09%
≥3 OAD cohort
95% CI upper
−0.93%
≥3 OAD cohort
Source sentences
Summary
Patients in the early dulaglutide therapy initiator group experienced larger reductions in HbA_1c levels (1 OAD: -1.39%; 95% CI, -1.50 to -1.27; 2 OADs: -1.30%; 95% CI, -1.39 to -1.20; and ≥3 OADs: -1.01%; 95% CI, -1.09 to -0.93) versus the patients in the delayed initiator group.
4 context sentences(design, population, supporting numbers)
Summary · context
The HbA_1c assessment (n = 3178) included 761 patients in the 1 OAD cohort, 1088 patients in the 2 OADs cohort, and 1329 patients in the ≥3 OADs cohort.
Summary · context
This retrospective, claims-based analysis evaluated adults with type 2 diabetes, ≥1 claim for dulaglutide 0.75 mg or 1.5 mg once-weekly injection (between November 2014 and August 2019), and no prior use of glucagon-like peptide 1 receptor agonists or insulin.
Summary · context
Cohorts were defined based on the number of oral antidiabetic drug (OAD) classes used within the 24-month baseline period before dulaglutide therapy initiation: 1 OAD, 2 OADs, or ≥3 OADs.
Summary · context
Six-month follow-up outcomes, including change in glycosylated hemoglobin (HbA_1c) and treatment patterns, were descriptively assessed within each cohort.
Report a problemFND-3561857106
02HumanObservational studyEfficacy outcome
In adults with ≥3 prior OAD classes, 33% achieved HbA1c <7% after dulaglutide initiation.
In plain wordsOne third of adults with at least three prior oral drug classes reached the blood sugar target after dulaglutide initiation.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableHbA1c below 7%, at least three prior OAD classes
Study
n = 1,329
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg or 1.5 mg once weekly · injection · 6 monthsAs given in this study (human).
Measurements
HbA1c <7%
33%
≥3 OAD cohort
Source sentences
Summary
Patients in the early dulaglutide therapy initiator group also achieved HbA_1c <7% at 6-month follow-up more frequently than those in the later initiator group (1 OAD: 68%; 2 OADs: 51%; and ≥3 OADs: 33%).
4 context sentences(design, population, supporting numbers)
Summary · context
The HbA_1c assessment (n = 3178) included 761 patients in the 1 OAD cohort, 1088 patients in the 2 OADs cohort, and 1329 patients in the ≥3 OADs cohort.
Summary · context
This retrospective, claims-based analysis evaluated adults with type 2 diabetes, ≥1 claim for dulaglutide 0.75 mg or 1.5 mg once-weekly injection (between November 2014 and August 2019), and no prior use of glucagon-like peptide 1 receptor agonists or insulin.
Summary · context
Cohorts were defined based on the number of oral antidiabetic drug (OAD) classes used within the 24-month baseline period before dulaglutide therapy initiation: 1 OAD, 2 OADs, or ≥3 OADs.
Summary · context
Six-month follow-up outcomes, including change in glycosylated hemoglobin (HbA_1c) and treatment patterns, were descriptively assessed within each cohort.
Report a problemFND-3561857109
03HumanObservational studyEfficacy outcome
In adults with two prior OAD classes, dulaglutide initiation was linked to an HbA1c reduction of -1.30%.
In plain wordsIn adults with two prior oral drug classes, dulaglutide initiation was linked to lower blood sugar than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change, two prior OAD classes
Study
n = 1,088
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg or 1.5 mg once weekly · injection · 6 monthsAs given in this study (human).
Measurements
HbA1c change
−1.3%
2 OAD cohort
95% CI lower
−1.39%
2 OAD cohort
95% CI upper
−1.2%
2 OAD cohort
Source sentences
Summary
Patients in the early dulaglutide therapy initiator group experienced larger reductions in HbA_1c levels (1 OAD: -1.39%; 95% CI, -1.50 to -1.27; 2 OADs: -1.30%; 95% CI, -1.39 to -1.20; and ≥3 OADs: -1.01%; 95% CI, -1.09 to -0.93) versus the patients in the delayed initiator group.
4 context sentences(design, population, supporting numbers)
Summary · context
The HbA_1c assessment (n = 3178) included 761 patients in the 1 OAD cohort, 1088 patients in the 2 OADs cohort, and 1329 patients in the ≥3 OADs cohort.
Summary · context
This retrospective, claims-based analysis evaluated adults with type 2 diabetes, ≥1 claim for dulaglutide 0.75 mg or 1.5 mg once-weekly injection (between November 2014 and August 2019), and no prior use of glucagon-like peptide 1 receptor agonists or insulin.
Summary · context
Cohorts were defined based on the number of oral antidiabetic drug (OAD) classes used within the 24-month baseline period before dulaglutide therapy initiation: 1 OAD, 2 OADs, or ≥3 OADs.
Summary · context
Six-month follow-up outcomes, including change in glycosylated hemoglobin (HbA_1c) and treatment patterns, were descriptively assessed within each cohort.
Report a problemFND-3561857105
04HumanObservational studyEfficacy outcome
In adults with two prior OAD classes, 51% achieved HbA1c <7% after dulaglutide initiation.
In plain wordsAbout half of adults with two prior oral drug classes reached the blood sugar target after dulaglutide initiation.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableHbA1c below 7%, two prior OAD classes
Study
n = 1,088
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg or 1.5 mg once weekly · injection · 6 monthsAs given in this study (human).
Measurements
HbA1c <7%
51%
2 OAD cohort
Source sentences
Summary
Patients in the early dulaglutide therapy initiator group also achieved HbA_1c <7% at 6-month follow-up more frequently than those in the later initiator group (1 OAD: 68%; 2 OADs: 51%; and ≥3 OADs: 33%).
4 context sentences(design, population, supporting numbers)
Summary · context
The HbA_1c assessment (n = 3178) included 761 patients in the 1 OAD cohort, 1088 patients in the 2 OADs cohort, and 1329 patients in the ≥3 OADs cohort.
Summary · context
This retrospective, claims-based analysis evaluated adults with type 2 diabetes, ≥1 claim for dulaglutide 0.75 mg or 1.5 mg once-weekly injection (between November 2014 and August 2019), and no prior use of glucagon-like peptide 1 receptor agonists or insulin.
Summary · context
Cohorts were defined based on the number of oral antidiabetic drug (OAD) classes used within the 24-month baseline period before dulaglutide therapy initiation: 1 OAD, 2 OADs, or ≥3 OADs.
Summary · context
Six-month follow-up outcomes, including change in glycosylated hemoglobin (HbA_1c) and treatment patterns, were descriptively assessed within each cohort.
Report a problemFND-3561857108
05HumanObservational studyEfficacy outcome
In adults with one prior OAD class, dulaglutide initiation was linked to an HbA1c change of -1.39% from baseline at 6 months.
In plain wordsIn adults with one prior oral drug class, dulaglutide initiation was linked to lower blood sugar than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change, one prior OAD class
Study
n = 761
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg or 1.5 mg once weekly · injection · 6 monthsAs given in this study (human).
Measurements
HbA1c change
−1.39%
1 OAD cohort
95% CI lower
−1.5%
1 OAD cohort
95% CI upper
−1.27%
1 OAD cohort
Source sentences
Summary
Patients in the early dulaglutide therapy initiator group experienced larger reductions in HbA_1c levels (1 OAD: -1.39%; 95% CI, -1.50 to -1.27; 2 OADs: -1.30%; 95% CI, -1.39 to -1.20; and ≥3 OADs: -1.01%; 95% CI, -1.09 to -0.93) versus the patients in the delayed initiator group.
4 context sentences(design, population, supporting numbers)
Summary · context
The HbA_1c assessment (n = 3178) included 761 patients in the 1 OAD cohort, 1088 patients in the 2 OADs cohort, and 1329 patients in the ≥3 OADs cohort.
Summary · context
This retrospective, claims-based analysis evaluated adults with type 2 diabetes, ≥1 claim for dulaglutide 0.75 mg or 1.5 mg once-weekly injection (between November 2014 and August 2019), and no prior use of glucagon-like peptide 1 receptor agonists or insulin.
Summary · context
Cohorts were defined based on the number of oral antidiabetic drug (OAD) classes used within the 24-month baseline period before dulaglutide therapy initiation: 1 OAD, 2 OADs, or ≥3 OADs.
Summary · context
Six-month follow-up outcomes, including change in glycosylated hemoglobin (HbA_1c) and treatment patterns, were descriptively assessed within each cohort.
Report a problemFND-3561857104

Studies that did not test the peptide alone4

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In US adults with diabetes, most dulaglutide initiators started at 0.75 mg.
In plain wordsMost adults in the claims study started dulaglutide at the lower dose.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableInitial dose
Study
n = 18,121
Outcome group
Patterns of use · Pharmacology
Measurements
Initiation at 0.75 mg
67 to 70%
cohorts
Source sentences
Summary
Most patients (67%-70%) initiated treatment with dulaglutide 0.75 mg.
3 context sentences(design, population, supporting numbers)
Summary · context
This retrospective, claims-based analysis evaluated adults with type 2 diabetes, ≥1 claim for dulaglutide 0.75 mg or 1.5 mg once-weekly injection (between November 2014 and August 2019), and no prior use of glucagon-like peptide 1 receptor agonists or insulin.
Summary · context
Cohorts were defined based on the number of oral antidiabetic drug (OAD) classes used within the 24-month baseline period before dulaglutide therapy initiation: 1 OAD, 2 OADs, or ≥3 OADs.
Summary · context
Six-month follow-up outcomes, including change in glycosylated hemoglobin (HbA_1c) and treatment patterns, were descriptively assessed within each cohort.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3561857101
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In US adults with diabetes, dulaglutide dose escalation was uncommon but trended higher with more prior OAD classes.
In plain wordsDose escalation was uncommon and tended to be higher among adults with more prior oral diabetes drug classes.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseDose escalation
Study
n = 18,121
Comparator
Cohorts with fewer prior OAD classes
Outcome group
Patterns of use · Pharmacology
Measurements
Dose escalation
15 to 20%
to 1.5 mg
Source sentences
Summary
Dose escalation to 1.5 mg was uncommon (15%-20%) but trended higher in the ≥3 OAD cohort.
3 context sentences(design, population, supporting numbers)
Summary · context
This retrospective, claims-based analysis evaluated adults with type 2 diabetes, ≥1 claim for dulaglutide 0.75 mg or 1.5 mg once-weekly injection (between November 2014 and August 2019), and no prior use of glucagon-like peptide 1 receptor agonists or insulin.
Summary · context
Cohorts were defined based on the number of oral antidiabetic drug (OAD) classes used within the 24-month baseline period before dulaglutide therapy initiation: 1 OAD, 2 OADs, or ≥3 OADs.
Summary · context
Six-month follow-up outcomes, including change in glycosylated hemoglobin (HbA_1c) and treatment patterns, were descriptively assessed within each cohort.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3561857102
08HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In US adults with diabetes, dulaglutide adherence at follow-up increased with higher baseline OAD use.
In plain wordsHigher prior oral diabetes drug use was linked to higher dulaglutide adherence.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseAdherence
Study
n = 18,121
Comparator
Lower baseline OAD use
Outcome group
Treatment adherence and retention · Pharmacology
Measurements
Adherence
61 to 67%
6-month follow-up
Source sentences
Summary
Adherence to dulaglutide at 6-month follow-up (61%-67%) increased with higher baseline OAD use.
3 context sentences(design, population, supporting numbers)
Summary · context
This retrospective, claims-based analysis evaluated adults with type 2 diabetes, ≥1 claim for dulaglutide 0.75 mg or 1.5 mg once-weekly injection (between November 2014 and August 2019), and no prior use of glucagon-like peptide 1 receptor agonists or insulin.
Summary · context
Cohorts were defined based on the number of oral antidiabetic drug (OAD) classes used within the 24-month baseline period before dulaglutide therapy initiation: 1 OAD, 2 OADs, or ≥3 OADs.
Summary · context
Six-month follow-up outcomes, including change in glycosylated hemoglobin (HbA_1c) and treatment patterns, were descriptively assessed within each cohort.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3561857103
09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In adults with one prior OAD class, early dulaglutide initiation was linked to more frequent HbA1c target achievement than later initiation.
In plain wordsEarlier dulaglutide initiation was linked to more frequent blood sugar target achievement than later initiation.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHbA1c below 7%, one prior OAD class
Study
n = 761
Comparator
Later initiator cohorts
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c <7%
68%
1 OAD cohort
Source sentences
Summary
Patients in the early dulaglutide therapy initiator group also achieved HbA_1c <7% at 6-month follow-up more frequently than those in the later initiator group (1 OAD: 68%; 2 OADs: 51%; and ≥3 OADs: 33%).
4 context sentences(design, population, supporting numbers)
Summary · context
The HbA_1c assessment (n = 3178) included 761 patients in the 1 OAD cohort, 1088 patients in the 2 OADs cohort, and 1329 patients in the ≥3 OADs cohort.
Summary · context
This retrospective, claims-based analysis evaluated adults with type 2 diabetes, ≥1 claim for dulaglutide 0.75 mg or 1.5 mg once-weekly injection (between November 2014 and August 2019), and no prior use of glucagon-like peptide 1 receptor agonists or insulin.
Summary · context
Cohorts were defined based on the number of oral antidiabetic drug (OAD) classes used within the 24-month baseline period before dulaglutide therapy initiation: 1 OAD, 2 OADs, or ≥3 OADs.
Summary · context
Six-month follow-up outcomes, including change in glycosylated hemoglobin (HbA_1c) and treatment patterns, were descriptively assessed within each cohort.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3561857107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.